This study aimed to analysis outcome and prognosis of interstitial 125 I seed implantation in patients with cervical lymph node recurrence after multimodal treatment of thoracic esophageal squamous cell carcinoma (ESCC). We conducted a retrospective review of 19 patients with 32 cervical lymph nodes recurrences after multimodal treatment (lymphadenectomy, radiotherapy, chemotherapy, and various combinations of these treatments) of thoracic ESCC, who underwent 125 I seed implantation in our department from 2003 to 2011. All the patients were followed up until expiration and the median duration of follow up was 7 months (range, 3-44 months). Syndromes significantly improved after implantation. The local control rates after 3, 6, 12, and 24 months were 84.2%, 63.2%, 32.0%, and 26.0%, respectively, with a median of 10 months. The median overall survival time was 7 months (95% CI, 5.6-8.4), and 1-and 2-year survival rates were 31.6% and 10.5%, respectively. Among these patients, there were 11 died of progression of disease (PD) 3-44 months after implantation. One The N stage, number of recurrent nodes and recurrence interval time are factors influencing tumor local control, and the recurrence interval time is independent factor influencing survival after percutaneous 125 I seed implantation in ESCC with cervical lymph node recurrence.
Introduction
Esophageal carcinoma is one of the main causes of cancer-related death in the world (1) . In China, the predominant histological type is squamous cell carcinoma
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(SCC) (2) . Most patients diagnosed with esophageal cancer have advanced disease, and long-term survival is poor. Although recent advances in treatment techniques have improved overall survival (3, 4) , lymph node recurrence still is one of the most frequent patterns of recurrence even after multimodal treatment (5) . If lymph node recurrence is treated effectively, relatively long term survival may be possible (6, 7) . However, treatment of esophageal cancer with lymph node recurrence is usually challenging because the previous therapies (including lymphadenectomy, radio therapy, chemo therapy, and various combinations of these treatments) limit the options available for salvage treatment. The optimal treatment of these recurrent patients has remained controversial (8, 9) .
The interstitial implantation of 125 I seeds has been developed extensively in the last 20 years, and plays a very important role in the salvage treatment of many malignancies, both in the local control of cancer as well as in the control of metastatic disease (10) (11) (12) . The characteristics of 125 I seed implantation are safety, low energy, sustained accumulated radiation, and homogenous dose distribution in the target area. In addition, interstitial permanent 125 I seed implantation creates sharp dose gradients between tumor and adjacent normal tissues, thus allowing more sparing of the organs at risk. High-radiation doses at the tumor and more effective delivery of radiation of this treatment approach seemed to be an effective salvage treatment, with the goal of increasing the cure rate of cancer (13) . However, there are few reports about the effects of metastatic lymph nodes with this method. This research retrospectively evaluated the clinical outcome of interstitial 125 I seed implantation for cervical metastatic lymph nodes recurrence from esophageal carcinoma.
Materials and Methods

Patients
Eligibility criteria were as follows: informed consent before undergoing seed implantation; diagnosed thoracic ESCC pathologically; identified larger than 1.0 cm in short-axis diameter on CT or ultrasonography; and Karnofsky performance status (KPS) 60. Prior to implantation, medical history, physical examination, routine hematology and biochemical analyses, and CT/ultrasonography of the cervical lymph nodes were undertaken. TNM staging was performed according to the criteria of the Union for International Cancer Control (UICC) (14) . Table I . Sixteen males and 3 females, with a median age of 60 years (range, 48-78 years). Prior treatment was surgical resection in 1 (5.2%) patient, chemoradiotherapy in 12 (63.2%) patients, and surgical resection combined with chemoradiotherapy in 6 (31.6%) patients. The metastatic cervical lymph node was identified 3-36 months (mean, 14 months) after the first treatment of the primary tumor. In all 19 cases, 6 (31.6%) showed hoarseness, 6 (31.6%) showed moderate pain or severe pain, and 2 (10.5%) showed aspirations. No other therapies were received during implantation because all the patients received previous treatment (lymphadenectomy, radiotherapy, chemotherapy, and various combinations of these treatments).
Pretreatment Planning
Details of lymph node volumes were assessed using ultrasonography/CT 1 to 2 days prior to seed implantation. A radiation oncologist outlined the gross tumor volume (GTV) and the organs at risk (OARs) with a computer treatment planning system (TPS) (3D treatment planning system, Beijing Feitian Industries Inc., Beijing, China). GTV was defined as metastatic lymph nodes measured 1 cm in the long axis and D90 (Prescribed doses delivered to 90% of the gross tumor volume) was 140-170 Gy. The total activity and number of 125 I seeds implanted at the target site were determined on the basis of our experience in previous studies (11, 12, 15) . Planning target volume (PTV) was defined as a 1.0 cm of expansion external to the GTV. PTV edge was covered by 90% isodose curve. The entry site and path of the needles were determined to avoid vital structures.
Seed Implantation Technique
All the patients received ultrasonography/CT-guided seed implantation under local anesthesia. Once the target volume had been determined, interstitial needles (18 Gauge) were inserted into the tumor. The puncture method during the implantation was multi-angle non-planar percutaneous puncture, mainly depended on the operator's experience. In order to prevent puncture of large vessels, needles were placed in parallel under image-guided in each transverse slice, and 0.5-1.0 cm apart according to the preplan. The seeds were implanted using a Mick applicator (Mick Radio-Nuclear Instruments Inc., Mount Vernon, NY, USA), and every seed was placed at a distance of 0.5-1.0 cm from each other.
Postoperative Dosimetry Evaluation
Postoperative dosimetry was routinely performed for all patients immediately. A radiation oncologist outlined the GTV and OARs in the TPS according to the site of implantation, and a routine check was performed to verify the position of 125 I seeds and generated the actual isodose distribution ( Figure 1 ). For tumors showing insufficient radioactivity, more 125 I seeds were implanted.
Follow Up
All the patients were followed up from the time of seed implantation to expiration. Tumor response was initially evaluated at 4 weeks and thereafter at intervals of 2 to 3 months. Disease status was assessed by physical examination, liver function tests, and full blood and platelet counts. Radiological measurement of disease progression, which included ultrasound examination and/or CT scans, was performed.
Statistical Analysis
All statistical analyses were conducted using SPSS version 19.0 (SPSS, Chicago, IL, USA). Survival time was defined from the start of implantation to expiration, and local progression-free survival (PFS) was defined from the start of implantation to PD or expiration. For univariate analysis, continuous variables were analyzed using t-test, and categorical variables were expressed as Chi Square-test. A p value  0.2 by univariate analysis were selected for inclusion in a multivariate logistic regression model to assess the independent effect of these variables on the implantation. A double-sided p value  0.05 was considered statistically significant. 
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Results
Outcome of 125 I Seed Implantation
All the patients were followed up until expiration and the median duration of follow up was 7 months (range, 3-44 months). Among all patients, 18 were successfully performed implantation at the first time, and 1 did not achieve the prescribed dose criteria, followed by additional implantation after immediate postoperative dosimetry. Median number of 125 I seeds implanted was 30 (range, 9-84). The specific activity of seeds ranged from 0.5 to 0.8 mCi per seed, with a median of 0.7 mCi/seed. Actual D90 were 123-204 Gy, with a median of 169 Gy in postoperative dosimetry evaluation. The clinical characteristics of patients performed implantation were summarized in Table II .
Effectiveness of
I Seed Implantation
Syndromes improved greatly, including hoarseness (3/6), local pain (6/6), and aspiration (1/2). The hoarseness and aspiration were all palliated within 3 months. The local pain grades greatly relieved 1-3 months after implantation. Before implantation the scores of pain were 4-7, and after implantation the scores of pain were 0-3.
The local control rates after 3, 6, 12, and 24 months were 84.2%, 63.2%, 32.0%, and 26.0%, respectively, with a median of 10 months. Eight (42.1%) patients presented good control of local tumor and no systemic recurrence and survived until acute myocardial infarction (2, 10.5%) and pulmonary infection (6, 31.6%).
The median overall survival time was 7 months (95% CI, 5.6-8.4), and 1-and 2-year survival rates were 31.6% and 10.5%, respectively. Among these patients, there were 11 (57.9%) died of PD 3-44 months after implantation, 8 (42.1%) died of hematogenous metastases, and 3 (15.8%) died of cahtexia.
Prognosis of 125 I Seed Implantation
In 
Side Effects
Several complications related to the procedure occurred after implantation. Two patients presented fever with 37.8 and 38.3C the day after implantation and alleviated by oneself without special processing in a couple of days. One patient presented grade IV skin toxic effect and repaired by free flap transplantation. No fatal complications such as massive bleeding happened.
Discussion
Lymph node status in patients with esophageal cancer is strongly associated with survival, and is indicative of short time survival, even for those undergoing multimodal treatment (16) (17) (18) (19) (20) . Although curative surgery and chemoradiotherapy have been improved survival, thoracic ESCC frequently relapses in the lymph nodes (9, 21, 22) . Clinical decision making is guided by many factors, including the availability of local surgical, radiotherapeutic expertise, any prior treatments the patient received, time to recurrence, performance status and predicted prognosis at relapse, as well as anticipated treatment-related morbidity. Many surgeons and oncologists believe that more radical treatment adds little to improving survival, but significantly affects morbidity and mortality (23) . Thus, there does not currently appear to be a clear optimal treatment that is suitable for patients with cervical lymph node recurrence of thoracic ESCC after multimodal treatment.
Permanent
125
I seed implantation technique has been used for many decades in the management of malignant tumors, due to its efficacy, safety, feasibility, and the fact that it is a minimally invasive treatment (10) (11) (12) . 125 I seed send out continuous low-dose X-ray and g-ray, delivery dose of 160-180 Gy within the local tissue during the half-life of 125 I. This specific effect of 125 I makes it is possible to inhibit the proliferation and repair of tumor cells, while the surrounding normal tissue only received less than 25% of the doses delivered to the tumor cells (24) . This continuous slowly emission of radiation from the 125 I seeds also allows the normal tissue that receives sublethal or potentially lethal dose of radiation to have sufficient time for repair and recover (25) . All these characteristics make it might be an optimal treatment for cervical lymph node metastases, especially for patients with recurrence who received multimodal treatment already.
Lymph node recurrence in esophageal cancer can be curative in a low percentage. The analysis of Shimada et al. found that the 1-year survival rate was 35% (26) , with a median survival of 7 months after recurrence in patients with regional recurrence that mostly involved the lymph node (27 (29) . The patients in our study who received implantation demonstrated a promised local control and survival rates. The local control rates after 3, 6, 12, and 24 months were 84.2%, 63.2%, 32.0%, and 26.0%, respectively, with a median of 10 months. The 1-and 2-year survival rates were 31.6% and 10.5%, respectively. At the time of expiration, 8 (42.1%) patients presented good control of local tumor and no systemic recurrence and survived until acute myocardial infarction (2, 10.5%) and pulmonary infection (6, 31.6%). Although the median overall survival time was 7 months (95% CI, 5.6-8.4), 6/19 (31.6%) patients who were alive without evidence of re-recurrence longer than 12 months after implantation are encouraging. For these patients, recurrence was limited within the cervical lymph nodes, 125 I seed implantation has been an optimal treatment.
The success of 125 I seeds implantation depends on the accurate placement of seeds within a known volume of tumor (30, 31) . Using image guidance, details of needles and seeds in the volume can be seen and the position of each needle and seed can be adjusted to ensure proper placement according to the pretreatment planning during implantation. The puncture method was multi-angle non-planar percutaneous puncture, mainly depended on the operator's experience. Seeds were ejected from the needles when the depth of the needles specified by the preplan is reached. Actuarial position of the seeds was adjusted during implantation to provide a highly conformal dose distribution and achieve significant sparing of clinical organs. Tissue deformations, which were caused by the inserting and retracting a needle in tumor, must be taken into account during the implant process to achieve the desired seeds placement. Additionally, image guidance during procedure, was allowing better control of implanting and reducing the risk of damaging important organs.
Two patients presented fever with 37.8 and 38.3C the day after implantation and alleviated by oneself without special processing in a couple of days. One patient presented grade IV skin toxic effect and repaired by free flap transplantation. No fatal complications including massive bleeding and radioactive damage on important organs in this report. The vital blood vessels and organs surrounding the tumor can be clearly displayed with image guidance, which allowed better control of implantation, supported that implanting with image guidance is a safe procedure.
The prognostic factors analysis demonstrated that N stage, number of recurrent nodes, and recurrence interval time were independent prognostic factors of the tumor local control (p 5 0.022, 0.019, and 0.001, respectively), and recurrence interval time was prognostic factor of the survival (p  0.001). Of the 12 patients with lymphatic invasion at the time of diagnosis, 6 (50%) patients survived no more than 1-year, while all 7 patients diagnosed N0 stage survived no more than 1-year. Reviewed patients' medical history, we found that chemoradiotherapy was more likely to be used when thoracic ESCC with lymph node invasions, which targeting the invaded nodes. This finding suggested that small lymphatic metastases, which cannot be detected by traditional techniques such as CT and ultrasonography, might already have occurred at the time of diagnosis (28) . These small lymphatic metastases were different from the micrometastasis detected by immunohistochemistry or other molecular biology methods, which has been proved to have negative influence on survival (28, 32, 33) . These lymphatic metastases already existed but were not big enough to be detected.
Median survival of all 7 (36.8%) patients showed recurrence within single region was 15 months, while it was only 6 months in patients showed recurrence in multiple regions. In line with the results of other studies, region of recurrence nodes (single or multiple) is the prognostic factor influencing survival after lymph node recurrence of thoracic ESCC (34) . The present study also demonstrated that patients with long recurrence time showed significantly higher survival after salvage implantation than those who had a short recurrence time.
We acknowledge the following limitations in our study. It was a retrospective study with 19 patients. More studies with a greater number of patients are needed, in order to explore the potential of 125 I seed implantation further as a therapeutic option for the treatment of lymph node recurrence in ESCC.
In conclusion, we found interstitial 125 I seed implantation in treatment of lymph node recurrence of ESCC has satisfactory effect in controlling local recurrence of lymph node metastasis with low morbidity and mortality. Actual long term survival of interstitial 125 I seed implantation in patients with cervical lymph node recurrence in thoracic ESCC associated with single region of recurrent nodes and long interval time of recurrence.
